Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

0 avis

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Archive ouverte

Edité par CCSD ; BioMed Central -

International audience

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Adenovirus-specific T cell subsets in human peripheral blood and after IFN-g immunomagnetic selection

Archive ouverte | Qian, Chongsheng | CCSD

International audience. Adoptive antiviral cellular immunotherapy by infusion of virus-specific T cells (VSTs) is becoming an alternative treatment for viral infection after hematopoietic stem cell transplantation. ...

On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patients

Archive ouverte | Leroyer, Esther Hazane | CCSD

International audience

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy

Archive ouverte | Wang, Yingying | CCSD

International audience. Background: Epstein-Barr virus (EBV) infection is a major cause of morbidity following hematopoietic stem cell transplantation. EBV-infected B cells may not respond to rituximab treatment and...

Chargement des enrichissements...